Neuroinflammation in Alzheimer𠅩s disease

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2014, Pages 243-256

  Zhang, Fengjin ^a,b   Jiang, Linlan ^a  

^a GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^b SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Blood brain barrier; Glial cells; Inflammation; Inflammatory factors; Intracellular signaling pathways

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ASTROCYTE; BLOOD BRAIN BARRIER; CYTOKINE RELEASE; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; HUMAN; INTRACELLULAR SIGNALING; MEDIATOR RELEASE; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84923369208     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S75546     Document Type: Review

References (188)

1. Spencer JPE, Vafeiadou K, Williams RJ, Vauzour D. Neuroinflammation: modulation by flavonoids and mechanisms of action. Mol Aspects Med. 2012;33(1):83-97.
2. Hensley K. Neuroinflammation in Alzheimer’s disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. J Alzheimers Dis. 2010;21(1):1-14.
3. McGeer EG, McGeer PL. Neuroinflammation in Alzheimer’s disease and mild cognitive impairment: a field in its infancy. J Alzheimer Dis. 2010;19(1):355-361.
4. Brown GC, Bal-Price A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol Neurobiol. 2003;27(3):325-355.
5. Arima Y, Kamimura D, Sabharwal L, et al. Regulation of immune cell infiltration into the CNS by regional neural Inputs explained by the gate theory. Mediators Inflamm. 2013;2013:898165.
6. Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7(1):41-53.
7. Maeda T, Kanda T. Blood-brain barrier and blood-nerve barrier in neuroinflammatory diseases. Nippon Rinsho. 2013;71(5):789-794.
8. Syvanen S, Eriksson J. Advances in PET imaging of P-glycoprotein function at the blood-brain barrier. ACS Chem Neurosci. 2013;4(2):225-237.
9. Gheorghiu M, Enciu A-M, Popescu BO, Gheorghiu E. Functional and molecular characterization of the effect of amyloid-beta(42) on an in vitro epithelial barrier model. J Alzheimers Dis. 2014;38(4):787-798.
10. Burgmans S, van de Haar HJ, Verhey FRJ, Backes WH. Amyloid-beta interacts with blood-brain barrier function in dementia: a systematic review. J Alzheimers Dis. 2013;35(4):859-873.
11. Steinman L. Inflammatory cytokines at the summits of pathological signal cascades in brain diseases. Sci Signal. 2013;6(258):e3.
12. Carrano A, Hoozemans JJM, van der Vies SM, van Horssen J, de Vries HE, Rozemuller AJM. Neuroinflammation and blood-brain barrier changes in capillary amyloid angiopathy. Neurodegene Dis. 2012;10(1-4):329-331.
13. Rivest S, Lacroix S, Vallières L, Nadeau S, Zhang J, Laflamme N. How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic inflammatory and infectious stimuli. Proc Soc Exp Biol Med. 2000;223(1):22-38.
14. Takeda S, Sato N, Ikimura K, Nishino H, Rakugi H, Morishita R. Increased blood-brain barrier vulnerability to systemic inflammation in an Alzheimer disease mouse model. Neurobiol Aging. 2013;34(8):2064-2070.
15. Mischelevich DJ, Inventor; MISCHELEVICH DJ, (MISC-Individual), assignee. Method for altering permeability of blood-brain barrier in patient for use in treatment of eg., Alzheimer disease, involves energizing transducer to deliver pulsed ultrasound energy to target in brain or spinal cord. US patent US2013079682-A1. 2013 Mar 28.
16. Serrano-Pozo A, Mielke ML, Gómez-Isla T, et al. Reactive Glia not only associates with plaques but also parallels tangles in Alzheimer’s disease. Am J Pathol. 2011;179(3):1373-1384.
17. Heneka MT, O’Banion MK. Inflammatory processes in Alzheimer’s disease. J Neuroimmunol. 2007;184(1):69-91.
18. Czeh M, Gressens P, Kaindl AM. The yin and yang of microglia. Dev Neurosci. 2011;33(3-4):199-209.
19. Ginhoux F, Lim S, Hoeffel G, Low D, Huber T. Origin and differentiation of microglia. Front Cell Neurosci. 2013;17:7.
20. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140(6):918-934.
21. Greter M, Merad M. Regulation of microglia development and homeostasis. Glia. 2013;61(1):121-127.
22. Block ML, Zecca L, Hong J-S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8(1):57-69.
23. Harry GJ, Kraft AD. Microglia in the developing brain: a potential target with lifetime effects. Neurotoxicology. 2012;33(2):191-206.
24. Morales I, Jimenez JM, Mancilla M, Maccioni RB. Tau oligomers and fibrils induce activation of microglial cells. J Alzheimers Dis. 2013;37(4):849-856.
25. Rodriguez JJ, Witton J, Olabarria M, Noristani HN, Verkhratsky A. Increase in the density of resting microglia precedes neuritic plaque formation and microglial activation in a transgenic model of Alzheimer’s disease. Cell Death Dis. 2010;1:e1.
26. Griciuc A, Serrano-Pozo A, Parrado AR, et al. Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013;78(4):631-643.
27. Scheffler K, Stenzel J, Krohn M, et al. Determination of spatial and temporal distribution of microglia by 230 nm-high-resolution, high-throughput automated analysis reveals different amyloid plaque populations in an APP/PS1 mouse model of Alzheimer’s disease. Curr Alzheimer Res. 2011;8(7):781-788.
28. Du Yan S, Chen X, Fu J, et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer’s disease. Nature. 1996;382(6593):685-691.
29. El Khoury J, Hickman S, Thomas C, Loike J, Silverstein S. Microglia, scavenger receptors, and the pathogenesis of Alzheimer’s disease. Neurobiol Aging. 1998;19(1):S81-S84.
30. Leissring MA, Farris W, Chang AY, et al. Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003;40(6):1087-1093.
31. Li W, Poteet E, Xie L, Liu R, Wen Y, Yang S-H. Regulation of matrix metalloproteinase 2 by oligomeric amyloid β protein. Brain Res. 2011;1387:141-148.
32. Liu B, Hong J-S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther. 2003;304(1):1-7.
33. Naert G, Rivest S. The role of microglial cell subsets in Alzheimer’s disease. Curr Alzheimer Res. 2011;8(2):151-155.
34. Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective β-amyloid clearance pathways in aging Alzheimer’s disease mice. J Neurosci. 2008;28(33):8354-8360.
35. Floden AM, Combs CK. Microglia demonstrate age-dependent interaction with amyloid-beta fibrils. J Alzheimers Dis. 2011;25(2):279-293.
36. Krabbe G, Halle A, Matyash V, et al. Functional impairment of microglia coincides with beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS One. 2013;8(4):e60921.
37. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10(11):1387-1394.
38. Heneka MT, Kummer MP, Stutz A, et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature. 2012;493(7434):674-678.
39. Sherwood CC, Stimpson CD, Raghanti MA, et al. Evolution of increased glia-neuron ratios in the human frontal cortex. Proc Natl Acad Sci U S A. 2006;103(37):13606-13611.
40. Chan WY, Kohsaka S, Rezaie P. The origin and cell lineage of microglia-new concepts. Brain Res Rev. 2007;53(2):344-354.
41. Molofsky AV, Krencik R, Ullian EM, et al. Astrocytes and disease: a neurodevelopmental perspective. Genes Dev. 2012;26(9):891-907.
42. Sun D, Jakobs TC. Structural remodeling of astrocytes in the injured CNS. Neuroscientist. 2012;18(6):567-588.
43. Sidoryk-Wegrzynowicz M, Wegrzynowicz M, Lee E, Bowman AB, Aschner M. Role of astrocytes in brain function and disease. Toxicol Pathol. 2011;39(1):115-123.
44. Carrero I, Gonzalo MR, Martin B, Sanz-Anquela JM, Arevalo-Serrano J, Gonzalo-Ruiz A. Oligomers of beta-amyloid protein (A beta 1-42) induce the activation of cyclooxygenase-2 in astrocytes via an interaction with interleukin-1beta, tumour necrosis factor-alpha, and a nuclear factor kappa-B mechanism in the rat brain. Exp Neurol. 2012;236(2):215-227.
45. Medeiros R, LaFerla FM. Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony. Exp Neurol. 2013;239:133-138.
46. Crowe E, Bhat R, Bitto A, et al. Astrocyte senescence as a component of Alzheimer’s disease. Exp Gerontol. 2013;48(7):695-696.
47. Blasko I, Veerhuis R, Stampfer-Kountchev M, Saurwein-Teissl M, Eikelenboom P, Grubeck-Loebenstein B. Costimulatory effects of interferon-gamma and interleukin-1beta or tumor necrosis factor alpha on the synthesis of Abeta1-40 and Abeta1-42 by human astrocytes. Neurobiol Dis. 2000;7(6 pt B):682-689.
48. Yu Y, He J, Zhang Y, et al. Increased hippocampal neurogenesis in the progressive stage of Alzheimer’s disease phenotype in an APP/PS1 double transgenic mouse model. Hippocampus. 2009;19(12):1247-1253.
49. Tang BL. Neuronal protein trafficking associated with Alzheimer disease: from APP and BACE1 to glutamate receptors. Cell Adh Migr. 2009;3(1):118-128.
50. Hartlage-Rübsamen M, Zeitschel U, Apelt J, et al. Astrocytic expression of the Alzheimer’s disease β-secretase (BACE1) is stimulus-dependent. Glia. 2003;41(2):169-179.
51. Roßner S, Lange-Dohna C, Zeitschel U, Perez-Polo JR. Alzheimer’s disease β-secretase BACE1 is not a neuron-specific enzyme. J Neurochem. 2005;92(2):226-234.
52. Weggen S, Diehlmann A, Buslei R, Beyreuther K, Bayer T. Prominent expression of presenilin-1 in senile plaques and reactive astrocytes in Alzheimer’s disease brain. Neuroreport. 1998;9(14):3279-3283.
53. Zhao J, O’Connor T, Vassar R. The contribution of activated astrocytes to A beta production: implications for Alzheimer’s disease pathogenesis. J Neuroinflammation. 2011;2:8.
54. Miners JS, Van Helmond Z, Kehoe PG, Love S. Changes with age in the activities of β-secretase and the Aβ-degrading enzymes neprilysin, insulin-degrading enzyme and angiotensin-converting enzyme. Brain Pathol. 2010;20(4):794-802.
55. Apelt J, Ach K, Schliebs R. Aging-related down-regulation of neprilysin, a putative β-amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of β-amyloid plaques. Neurosci Lett. 2003;339(3):183-186.
56. Rossello XS, Igbavboa U, Weisman GA, Sun GY, Wood WG. AP-2 beta regulates amyloid beta-protein stimulation of apolipoprotein E transcription in astrocytes. Brain Res. 2012;1444:87-95.
57. Rossi D, Volterra A. Astrocytic dysfunction: insights on the role in neurodegeneration. Brain Res Bull. 2009;80(4):224-232.
58. Qin H, Benveniste EN. ELISA methodology to quantify astrocyte production of cytokines/chemokines in vitro. Methods Mol Biol. 2012;2012(814):235-249.
59. Talantova M, Sanz-Blasco S, Zhang X, et al. A beta induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A. 2013;110(27):E2518-E2527.
60. Bhat R, Crowe EP, Bitto A, et al. Astrocyte senescence as a component of Alzheimer’s disease. PLoS One. 2012;7(9):e45069.
61. Thal DR. The role of astrocytes in amyloid beta-protein toxicity and clearance. Exp Neurol. 2012;236(1):1-5.
62. Furman JL, Sama DM, Gant JC, et al. Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer’s disease. J Neurosci. 2012;32(46):16129-16140.
63. Krishna M, Narang H. The complexity of mitogen-activated protein kinases (MAPKs) made simple. Cell Mol Life Sci. 2008;65(22):3525-3544.
64. Wang X, Tournier C. Regulation of cellular functions by the ERK5 signalling pathway. Cell Signal. 2006;18(6):753-760.
65. Kyriakis JM, Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev. 2012;92(2):689-737.
66. Gerits N, Kostenko S, Moens U. In vivo functions of mitogen-activated protein kinases: conclusions from knock-in and knock-out mice. Transgenic Res. 2007;16(3):281-314.
67. Wagner EF, Nebreda ÁR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9(8):537-549.
68. Orejana L, Barros-Minones L, Aguirre N, Puerta E. Implication of JNK pathway on tau pathology and cognitive decline in a senescence-accelerated mouse model. Exp Gerontol. 2013;48(6):565-571.
69. Sclip A, Antoniou X, Colombo A, et al. c-Jun N-terminal kinase regulates soluble A beta oligomers and cognitive impairment in AD mouse model. J Biol Chem. 2011;286(51):43871-43880.
70. Shoji M, Iwakami N, Takeuchi S, et al. JNK activation is associated with intracellular β-amyloid accumulation. Mol Brain Res. 2000;85(1):221-233.
71. Lin W, Ding M, Xue J, Leng W. The role of TLR2/JNK/NF-kappa B pathway in amyloid beta peptide-induced inflammatory response in mouse NG108-15 neural cells. Int Immunopharmacol. 2013;17(3):880-884.
72. Munoz L, Ammit AJ. Targeting p38 MAPK pathway for the treatment of Alzheimer’s disease. Neuropharmacology. 2010;58(3):561-568.
73. Lee YB, Schrader JW, Kim SU. p38 MAP kinase regulates TNF-α production in human astrocytes and microglia by multiple mechanisms. Cytokine. 2000;12(7):874-880.
74. Xing B, Xin T, Hunter RL, Bing G. Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt. J Neuroinflammation. 2008;5(4):1-11.
75. Giovannini MG, Scali C, Prosperi C, et al. β-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol Dis. 2002;11(2):257-274.
76. Matos M, Augusto E, Oliveira C, Agostinho P. Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: involvement of oxidative stress and mitogen-activated protein kinase cascades. Neuroscience. 2008;156(4):898-910.
77. Pawate S, Bhat NR. C-Jun N-terminal kinase (JNK) regulation of iNOS expression in glial cells: predominant role of JNK1 isoform. Antioxid Redox Signal. 2006;8(5-6):903-909.
78. Marcus JS, Karackattu SL, Fleegal MA, Sumners C. Cytokine-stimulated inducible nitric oxide synthase expression in astroglia: role of Erk mitogen-activated protein kinase and NF-κB. Glia. 2003;41(2):152-160.
79. Han JE, Choi JW. Control of JNK for an activation of NADPH oxidase in LPS-stimulated BV2 microglia. Arch Pharm Res. 2012;35(4):709-715.
80. Yenki P, Khodagholi F, Shaerzadeh F. Inhibition of phosphorylation of JNK suppresses A beta-induced ER stress and upregulates prosurvival mitochondrial proteins in rat hippocampus. J Mol Neurosci. 2013;49(2):262-269.
81. Lu D-Y, Leung Y-M, Su K-P. Interferon-alpha induces nitric oxide synthase expression and haem oxygenase-1 down-regulation in microglia: implications of cellular mechanism of IFN-alpha-induced depression. Int J Neuropsychopharmacol. 2013;16(2):433-444.
82. Xing B, Bachstetter AD, Van Eldik LJ. Deficiency in p38beta MAPK fails to inhibit cytokine production or protect neurons against inflammatory insult in in vitro and in vivo mouse models. PloS One. 2013;8(2):e56852-e56852.
83. Chang L, Jones Y, Ellisman MH, Goldstein LS, Karin M. JNK1 is required for maintenance of neuronal microtubules and controls phosphorylation of microtubule-associated proteins. Dev Cell. 2003;4(4):521-533.
84. Kelleher I, Garwood C, Hanger DP, Anderton BH, Noble W. Kinase activities increase during the development of tauopathy in htau mice. J Neurochem. 2007;103(6):2256-2267.
85. Lee JW, Lee YK, Ban JO, et al. Green tea (-)-epigallocatechin-3-gallate inhibits beta-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NF-kappa B pathways in mice. J Nutr. 2009;139(10):1987-1993.
86. Kim SJ, Jeong HJ, Lee KM, et al. Epigallocatechin-3-gallate suppresses NF-kappa B activation and phosphorylation of p38 MAPK and JNK in human astrocytoma U373MG cells. J Nutr Biochem. 2007;18(9):587-596.
87. Jana M, Dasgupta S, Liu X, Pahan K. Regulation of tumor necrosis factor-α expression by CD40 ligation in BV-2 microglial cells. J Neurochem. 2002;80(1):197-206.
88. Nakajima K, Matsushita Y, Tohyama Y, Kohsaka S, Kurihara T. Differential suppression of endotoxin-inducible inflammatory cytokines by nuclear factor kappa B (NFκB) inhibitor in rat microglia. Neurosci Lett. 2006;401(3):199-202.
89. Bhat NR, Feinstein DL, Shen Q, Bhat AN. p38 MAPK-mediated transcriptional activation of inducible nitric-oxide synthase in glial cells roles of nuclear factors, nuclear factor κB, cAMP response element-binding protein, CCAAT/enhance-binding protein-β, and activating transcription factor-2. J Biol Chem. 2002;277(33):29584-29592.
90. Dai Y-Q, Jin D-Z, Zhu X-Z, Lei D-L. Triptolide inhibits COX-2 expression via NF-kappa B pathway in astrocytes. Neurosci Res. 2006;55(2):154-160.
91. Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE. Inflammatory mechanisms in Alzheimer’s disease: inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists. J Neurosci. 2000;20(2):558-567.
92. Landreth G, Jiang Q, Mandrekar S, Heneka M. PPARγ agonists as therapeutics for the treatment of Alzheimer’s disease. Neurotherapeutics. 2008;5(3):481-489.
93. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 1986;46(5):705-716.
94. Hayden MS, Ghosh S. Shared principles in NF-κB signaling. Cell. 2008;132(3):344-362.
95. Mincheva-Tasheva S, Soler RM. NF-κB signaling pathways role in nervous system physiology and pathology. Neuroscientist. 2013;19(2):175-194.
96. Pugazhenthi S, Zhang Y, Bouchard R, Mahaffey G. Induction of an inflammatory loop by interleukin-1 beta and tumor necrosis factor-alpha involves NF-kappa B and STAT-1 in differentiated human neuroprogenitor cells. PLoS One. 2013;8(7):e69585.
97. Mir M, Tolosa L, Asensio VJ, Lladó J, Olmos G. Complementary roles of tumor necrosis factor alpha and interferon gamma in inducible microglial nitric oxide generation. J Neuroimmunol. 2008;204(1):101-109.
98. Koo JW, Russo SJ, Ferguson D, Nestler EJ, Duman RS. Nuclear factor-κB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc Natl Acad Sci U S A. 2010;107(6):2669-2674.
99. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest. 2001;107(2):135-142.
100. Barger SW, Mattson MP. Induction of neuroprotective κB-dependent transcription by secreted forms of the Alzheimer’s β-amyloid precursor. Mol Brain Res. 1996;40(1):116-126.
101. Buggia-Prevot V, Sevalle J, Rossner S, Checler F. NFκB-dependent control of BACE1 promoter transactivation by Aβ42. J Biol Chem. 2008;283(15):10037-10047.
102. Valerio A, Boroni F, Benarese M, et al. NF-κB pathway: a target for preventing β-amyloid (Aβ)-induced neuronal damage and Aβ42 production. Eur J Neurosci. 2006;23(7):1711-1720.
103. Chen CH, Zhou W, Liu S, et al. Increased NF-kappa B signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer’s disease. Int J Neuropsychopharmacol. 2012;15(1):77-90.
104. Niu YL, Zhang WJ, Wu P, et al. Expression of the apoptosis-related proteins caspase-3 and NF-κB in the hippocampus of Tg2576 mice. Neurosci Bull. 2010;26(1):37-46.
105. Chami L, Buggia-Prévot V, Duplan E, et al. Nuclear factor-kappa B regulates beta APP and beta-and gamma-secretases differently at physiological and supraphysiological A beta concentrations. J Biol Chem. 2012;287(29):24573-24584.
106. Paris D, Patel N, Quadros A, et al. Inhibition of Aβ production by NF-κB inhibitors. Neurosci Lett. 2007;415(1):11-16.
107. Sung S, Yang H, Uryu K, et al. Modulation of nuclear factor-κB activity by indomethacin influences Aβ levels but not Aβ precursor protein metabolism in a model of Alzheimer’s disease. Am J Pathol. 2004;165(6):2197-2206.
108. Ascolani A, Balestrieri E, Minutolo A, et al. Dysregulated NF-kappa B pathway in peripheral mononuclear cells of Alzheimer’s disease patients. Curr Alzheimer Res. 2012;9(1):128-137.
109. Kummer MP, Heneka MT. PPARs in Alzheimer’s disease. PPAR Res. 2008;2008:403896.
110. Kersten S. Peroxisome proliferator activated receptors and lipoprotein metabolism. PPAR Res. 2007;2008:132960.
111. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature. 2008;454(7203):470-477.
112. Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell. 2006;126(4):789-799.
113. de la Monte SM, Wands JR. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer’s disease. J Alzheimer Dis. 2006;9(2):167-181.
114. Chen YC, Wu JS, Tsai HD, et al. Peroxisome proliferator-activated receptor gamma (PPAR-gamma) and neurodegenerative disorders. Mol Neurobiol. 2012;46(1):114-124.
115. Wada K, Nakajima A, Katayama K, et al. Peroxisome proliferator-activated receptor γ-mediated regulation of neural stem cell proliferation and differentiation. J Biol Chem. 2006;281(18):12673-12681.
116. Bright JJ, Kanakasabai S, Chearwae W, Chakraborty S. PPAR regulation of inflammatory signaling in CNS diseases. PPAR Res. 2008;2008:658520.
117. Esposito G, Scuderi C, Valenza M, et al. Cannabidiol reduces Ab-induced neuroinflammation and promotes hippocampal neurogenesis through PPAR gamma involvement. PLoS One. 2011;6(12):e28668.
118. Landreth G. Therapeutic use of agonists of the nuclear receptor PPAR in Alzheimers disease. Curr Alzheimer Res. 2007;4(2):159-164.
119. Neumann KF, Rojo L, Navarrete LP, Farías G, Reyes P, Maccioni RB. Insulin resistance and Alzheimer’s disease: molecular links clinical implications. Curr Alzheimer Res. 2008;5(5):438-447.
120. Jiang Q, Heneka M, Landreth GE. The role of peroxisome proliferator-activated receptor-γ PPARγ) in Alzheimer’s disease. CNS Drugs. 2008;22(1):1-14.
121. Zolezzi JM, Silva-Alvarez C, Ordenes D, et al. Peroxisome proliferator-activated receptor (PPAR) gamma and PPAR alpha agonists modulate mitochondrial fusion-fission dynamics: relevance to reactive oxygen species (ROS)-related neurodegenerative disorders? PLoS One. 2013;8(5):e64019.
122. Heneka MT, Sastre M, Dumitrescu-Ozimek L, et al. Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1-42 levels in APPV717I transgenic mice. Brain. 2005;128(6):1442-1453.
123. Gray E, Ginty M, Kemp K, Scolding N, Wilkins A. The PPAR-gamma agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function. J Neuroinflammation. 2012;5:9.
124. d’Abramo C, Ricciarelli R, Pronzato MA, Davies P. Troglitazone, a peroxisome proliferator-activated receptor-γ agonist, decreases tau phosphorylation in CHOtau4R cells. J Neurochem. 2006;98(4):1068-1077.
125. Wang G, Namura S. Effects of chronic systemic treatment with peroxisome proliferator-activated receptor alpha activators on neuroinflammation induced by intracerebral injection of lipopolysaccharide in adult mice. Neurosci Res. 2011;70(2):230-237.
126. Schnegg CI, Kooshki M, Hsu F-C, Sui G, Robbins ME. PPAR delta prevents radiation-induced proinflammatory responses in microglia via transrepression of NF-kappa B and inhibition of the PK alpha/MEK1/2/ERK1/2/AP-1 pathway. Free Radic Biol Med. 2012;52(9):1734-1743.
127. Barroso E, del Valle J, Porquet D, et al. Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPAR beta/delta-null mice. Biochim Biophys Acta. 2013;1832(8):1241-1248.
128. Sharma V, Thakur V, Singh SN, Guleria R. Tumor necrosis factor and Alzheimer’s disease: a cause and consequence relationship. Klinik Psikofarmakoloji B. 2012;22(1):86-97.
129. Swardfager W, Lanctôt K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer’s disease. Biol Psychiatry. 2010;68(10):930-941.
130. Gezen-Ak D, Dursun E, Hanağası H, et al. BDNF, TNF alpha, HSP90, CFH, and IL-10 serum levels in patients with early or late onset Alzheimer’s disease or mild cognitive impairment. J Alzheimers Dis. 2013;37(1):185-195.
131. McAlpine FE, Lee JK, Harms AS, et al. Inhibition of soluble TNF signaling in a mouse model of Alzheimer’s disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis. 2009;34(1):163-177.
132. Yamamoto M, Kiyota T, Horiba M, et al. Interferon-γ and tumor necrosis factor-α regulate amyloid-β plaque deposition and β-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol. 2007;170(2):680-692.
133. Liao Y-F, Wang B-J, Cheng H-T, Kuo L-H, Wolfe MS. Tumor necrosis factor-α, interleukin-1β, and interferon-γ stimulate γ-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J Biol Chem. 2004;279(47):49523-49532.
134. Tweedie D, Ferguson RA, Fishman K, et al. Tumor necrosis factor-alpha synthesis inhibitor 3,6′-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer’s disease. J Neuroinflammation. 2012;29:9.
135. Uslu S, Akarkarasu ZE, Ozbabalik D, et al. Levels of amyloid beta-42, interleukin-6 and tumor necrosis factor-alpha in Alzheimer’s disease and vascular dementia. Neurochem Res. 2012;37(7):1554-1559.
136. Kornman KS. Interleukin 1 genetics, inflammatory mechanisms, and nutrigenetic opportunities to modulate diseases of aging. Am J Clin Nutr. 2006;83(2):475S-483S.
137. Honma T, Hatta K, Hitomi Y, et al. Increased systemic inflammatory interleukin-1 beta and interleukin-6 during agitation as predictors of Alzheimer’s disease. Int J Geriatr Psychiatry. 2013;28(3):233-241.
138. Payão SL, Gonçalves GM, de Labio RW, et al. Association of interleukin 1 beta polymorphisms and haplotypes with Alzheimer’s disease. J Neuroimmunol. 2012;247(1-2):59-62.
139. Rogers JT, Leiter LM, McPhee J, et al. Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5′-untranslated region sequences. J Biol Chem. 1999;274(10):6421-6431.
140. Liu L, Aboud O, Jones RA, Mrak RE, Griffin S, Barger SW. Apolipoprotein E expression is elevated by interleukin 1 and other interleukin 1-induced factors. J Neuroinflammation. 2011;8:175.
141. Sheng JG, Jones RA, Zhou XQ, et al. Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer’s disease: potential significance for tau protein phosphorylation. Neurochem Int. 2001;39(5):341-348.
142. Griffin WST, Liu L, Li Y, Mrak RE, Barger SW. Interleukin-1 mediates Alzheimer and Lewy body pathologies. J Neuroinflammation. 2006;3(1):5.
143. Ghosh S, Wu MD, Shaftel SS, et al. Sustained interleukin-1 beta overexpression exacerbates tau pathology despite reduced Amyloid burden in an Alzheimer’s mouse model. J Neurosci. 2013;33(11):5053-5064.
144. Hein AM, Stutzman DL, Bland ST, et al. Prostaglandins are necessary and sufficient to induce contextual fear learning impairments after interleukin-1 beta injections into the dorsal hippocampus. Neuroscience. 2007;150(4):754-763.
145. Hein AM, Stasko MR, Matousek SB, et al. Sustained hippocampal IL-1β overexpression impairs contextual and spatial memory in transgenic mice. Brain Behav Immun. 2010;24(2):243-253.
146. Matousek SB, Ghosh S, Shaftel SS, Kyrkanides S, Olschowka JA, O’Banion MK. Chronic IL-1 beta-mediated neuroinflammation mitigates amyloid pathology in a mouse model of Alzheimer’s disease without inducing overt neurodegeneration. J Neuroimmune Pharmacol. 2012;7(1):156-164.
147. Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci. 2012;8(9):1254-1266.
148. Serretti A, Olgiati P, De Ronchi D. Genetics of Alzheimer’s disease. A rapidly evolving field. J Alzheimer Dis. 2007;12(1):73-92.
149. Chen SY, Chen TF, Lai LC, et al. Sequence variants of interleukin 6 (IL-6) are significantly associated with a decreased risk of late-onset Alzheimer’s disease. J Neuroinflammation. 2012;24:9.
150. Qi H-P, Qu Z-Y, Duan S-R, Wei S-Q, Wen S-R, Bi S. IL-6-174 G/C and-572 C/G polymorphisms and risk of Alzheimer’s disease. PLoS One. 2012;7(6):e37858.
151. Querfurth HW, LaFerla FM. Mechanisms of disease. N Engl J Med. 2010;362(4):329-344.
152. Quintanilla RA, Orellana DI, González-Billault C, Maccioni RB. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res. 2004;295(1):245-257.
153. Hua Y, Guo X, Huang Q, Kong Y, Lu X. Association between interleukin-6-174G/C polymorphism and the risk of Alzheimer’s disease: a meta-analysis. Int J Neurosci. 2013;123(9):626-635.
154. Szczepanik AM, Funes S, Petko W, Ringheim GE. IL-4, IL-10 and IL-13 modulate Aβ (1-42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. J Neuroimmunol. 2001;113(1):49-62.
155. Town T, Laouar Y, Pittenger C, et al. Blocking TGF-β-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med. 2008;14(6):681-687.
156. Kim J, Onstead L, Randle S, et al. Abeta40 inhibits amyloid deposition in vivo. J Neurosci. 2007;27(3):627-633.
157. Leung R, Proitsi P, Simmons A, et al. Inflammatory proteins in plasma are associated with severity of Alzheimer’s disease. PLoS One. 2013;8(6):e64971.
158. Dobolyi A, Vincze C, Pal G, Lovas G. The neuroprotective functions of transforming growth factor beta proteins. Int J Mol Sci. 2012;13(7):8219-8258.
159. Rota E, Bellone G, Rocca P, Bergamasco B, Emanuelli G, Ferrero P. Increased intrathecal TGF-β1, but not IL-12, IFN-γ and IL-10 levels in Alzheimer’s disease patients. Neurol Sci. 2006;27(1):33-39.
160. Motta M, Imbesi R, Di Rosa M, Stivala F, Malaguarnera L. Altered plasma cytokine levels in Alzheimer’s disease: correlation with the disease progression. Immunol Lett. 2007;114(1):46-51.
161. Morimoto K, Horio J, Satoh H, et al. Expression profiles of cytokines in the brains of Alzheimer’s disease (AD) patients compared to the brains of non-demented patients with and without increasing AD pathology. J Alzheimer Dis. 2011;25(1):59-76.
162. Lifshitz V, Weiss R, Benromano T, et al. Immunotherapy of cerebrovascular amyloidosis in a transgenic mouse model. Neurobiol Aging. 2012;33(2):e431-e432.
163. Huang L, Jia J, Liu R. Decreased serum levels of the angiogenic factors VEGF and TGF-beta1 in Alzheimer’s disease and amnestic mild cognitive impairment. Neurosci Lett. 2013;550:60-63.
164. Mocali A, Cedrola S, Della Malva N, et al. Increased plasma levels of soluble CD40, together with the decrease of TGFβ1, as possible differential markers of Alzheimer disease. Exp Gerontol. 2004;39(10):1555-1561.
165. Khoury JE, Luster AD. Mechanisms of microglia accumulation in Alzheimer’s disease: therapeutic implications. Trends Pharmacol Sci. 2008;29(12):626-632.
166. Caraci F, Spampinato S, Sortino MA, et al. Dysfunction of TGF-β1 signaling in Alzheimer’s disease: perspectives for neuroprotection. Cell Tissue Res. 2012;347(1):291-301.
167. Ma D, Doi Y, Jin S, et al. TGF-beta induced by interleukin-34-stimulated microglia regulates microglial proliferation and attenuates oligomeric amyloid beta neurotoxicity. Neurosci Lett. 2012;529(1):86-91.
168. Tichauer JE, von Bernhardi R. Transforming growth factor-beta stimulates beta amyloid uptake by microglia through Smad3-dependent mechanisms. J Neurosci Res. 2012;90(10):1970-1980.
169. Weiss R, Lifshitz V, Frenkel D. TGF-β1 affects endothelial cell interaction with macrophages and T-cells leading to the development of cerebrovascular amyloidosis. Brain Behav Immun. 2011;25(5):1017-1024.
170. Martinez-Canabal A, Wheeler AL, Sarkis D, et al. Chronic over-expression of TGF beta 1 alters hippocampal structure and causes learning deficits. Hippocampus. 2013;23(12):1198-1211.
171. Citron M. Alzheimer’s disease: strategies for disease modification. Nat Rev Drug Discov. 2010;9(5):387-398.
172. De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol. 2010;6(2):99-107.
173. Thal DR, von Arnim C, Griffin WS, et al. Pathology of clinical and preclinical Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci. 2013;263:S137-S145.
174. Palop JJ, Mucke L. Amyloid-[beta]-induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks. Nat Neurosci. 2010;13(7):812-818.
175. Vincent AJ, Gasperini R, Foa L, Small DH. Astrocytes in Alzheimer’s disease: emerging roles in calcium dysregulation and synaptic plasticity. J Alzheimers Dis. 2010;22(3):699-714.
176. Carrillo-Mora P, Luna R, Colin-Barenque L. Amyloid beta: multiple mechanisms of toxicity and only some protective effects? Oxid Med Cell Longev. 2014;2014:795375.
177. Zotova E, Bharambe V, Cheaveau M, et al. Inflammatory components in human Alzheimer’s disease and after active amyloid-beta(42) immunization. Brain. 2013;136:2677-2696.
178. Joseph-Mathurin N, Dorieux O, Trouche SG, et al. Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds. Neurobiol Aging. 2013;34(11):2613-2622.
179. Panza F, Logroscino G, Imbimbo BP, Solfrizzi V. Is there still any hope for amyloid-based immunotherapy for Alzheimer’s disease? Curr Opin Psychiatry. 2014;27(2):128-137.
180. Cohen TJ, Guo JL, Hurtado DE, et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun. 2011;2:252.
181. Iqbal K, Liu F, Gong C-X, Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res. 2010;7(8):656.
182. Min SW, Cho SH, Zhou Y, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 2010;67(6):953-966.
183. Morris M, Maeda S, Vossel K, Mucke L. The many faces of tau. Neuron. 2011;70(3):410-426.
184. Pooler AM, Noble W, Hanger DP. A role for tau at the synapse in Alzheimer’s disease pathogenesis. Neuropharmacology. 2014;76:1-8.
185. Arnaud L, Robakis NK, Figueiredo-Pereira ME. It may take inflammation, phosphorylation and ubiquitination to “tangle” in Alzheimer’s disease. Neurodegener Dis. 2006;3(6):313-319.
186. Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24(1):1121-1159.
187. Rozenstein-Tsalkovich L, Grigoriadis N, Lourbopoulos A, et al. Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation. Exp Neurol. 2013;248:451-456.
188. Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer’s disease: past, present and future. Neuropharmacology. 2014;76:27-50.